Medivir carries out a directed share issue of approx. SEK 20 million
Summary
The Directed Issue can be carried out in a time and cost-effective manner, which means that the Company can quickly benefit from a large part of the proceeds. Anders Hallberg has more than 20 years of experience in investing in health care and is one of the founders of the fund company Healthinvest Partners AB. The board of directors assessment is therefore that the subscription price has been set on market terms and reflects the current demand and market conditions.In connection with the Rights Issue, the Company undertook towards Pareto Securities AB and Zonda Partners AB not to issue additional shares or other share-related instruments for a period of 90 days after the end of the subscription period. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects.